The Parkinson's Foundation and the WHO Foundation have joined forces in a groundbreaking partnership, marking a significant step forward in global healthcare. This collaboration aims to address the critical issue of improving access to Parkinson's disease (PD) medications in Africa, a region often overlooked in global health initiatives. The partnership's primary goal is to tackle the treatment gap for neurological disorders, particularly PD, which disproportionately affects individuals in low- and middle-income countries (LMICs).
The announcement comes amidst the 2nd World Summit on Parkinson's Disease, hosted by the Parkinson's Foundation in collaboration with the Fresco Parkinson Institute Italia. This summit, held in Florence, Italy, brought together a diverse group of multidisciplinary experts, including neurologists, healthcare professionals, and researchers, to discuss the global impact of PD. The event highlighted the stark reality of unequal access to essential medicines, especially in LMICs, where exorbitant prices and insufficient efficacy data pose significant challenges.
Sneha Mantri, MD, MS, FAAN, the Parkinson's Foundation Chief Medical Officer, emphasizes the strategic importance of this partnership. She states, 'Our partnership with the WHO Foundation is a critical intervention to improve the lives of millions affected by neurological conditions, especially in low- and middle-income countries. This initiative aims to ensure equitable and reliable access to essential medications, addressing the socio-economic barriers and historical lack of prioritization that hinder effective neurological care.'
The partnership's impact extends beyond financial support. It serves as a catalyst for elevating the global discourse on neurological health. By collaborating with the WHO Foundation, the Parkinson's Foundation is actively contributing to the expansion of access to neurological medicines, thereby reducing the overall burden of neurological disorders worldwide. This initiative is a testament to the power of international cooperation in healthcare, where collective efforts can lead to tangible improvements in patient outcomes.
Catarina Mastellaro, Head of Strategic Engagement at the WHO Foundation, underscores the significance of this collaboration. She remarks, 'We are at a pivotal moment for brain health. Neurological conditions, including Parkinson's disease, demand increased attention. By supporting the WHO's efforts to expand access to neurological medicines, we can make substantial progress in closing the treatment gap.'
The World Summit on Parkinson's Disease, an invite-only event, serves as a platform for ongoing dialogue and collaboration. It is a testament to the commitment of these organizations to address the pressing needs of PD patients globally. This partnership and summit are crucial steps in the journey towards a more equitable and accessible healthcare system, ensuring that neurological disorders receive the attention and resources they deserve.
.png?itok=5VCM2PeV)
